Sorafenib <i>vs</i>. Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

Teiji Kuzuya(Nagoya University), Mitsuhiro Fujishiro(Bunkyo University), Masatoshi Ishigami(Nagoya University), Tetsuya Ishikawa(Nagoya University), Takanori Ito(Aichi Medical University Hospital), Yoji Ishizu(Nagoya University), Takashi Honda(Osaka Hospital)
Anticancer Research
March 31, 2020
Cited by 53


Related Papers